Ulrich patent opposition analysis

The comprehensive analysis of Ulrich opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Ulrich

Patent NumberTitleApplicantOpposition DateOpposition Company
Composition For Nasal Application With Improved StabilityMARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBHFeb 26, 2025RATIOPHARM
Enhancing Blood-Brain Barrier Drug Transport By Targeting Endogenous RegulatorsTHE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSJan 15, 2025DORRIES
Methods For Treating Skin Infection By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALS, INC.Nov 13, 2024DORRIES
Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALS, INC.Nov 7, 2024DORRIES
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMACEUTICALS, INC.Oct 28, 2024AMGEN TECHNOLOGY IRELAND UNLIMITED
Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITTSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITT MAINZ GEMEINNTZIGEOct 10, 2024DR H ULRICH DORRIES
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYOct 1, 2024DR H ULRICH DORRIES
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYAug 1, 2024DR H ULRICH DORRIES
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYJul 3, 2024DR H ULRICH DORRIES
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALS, INC.Feb 29, 2024AMGEN